Type I interferons are interferons that signal via binding to the interferon-alfa receptor (which in turn signals via the JAK-STAT pathway), they are produced by a variety of different cells, in response to viral pathogens and certain other triggers; these cells include: leucocytes, fibroblasts and lymphoblasts. They include interferon alfa and beta. Type I IFNs are upregulated in a few autoimmune diseases, most notably systemic lupus erythematosus and hence drugs that inhibit their signalling are being investigated as possible treatments for these disorders.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- ↑ 1.0 1.1 Kilbourne, J; Case, JT; Cho, DS; Hui, C; Jarnot, M; Koroma, B; Pash, J; Powell, T; Schulman, JL; Sorden, N (2015). "Interferon Type I". Medical Subject Headings. Bethesda, USA: U.S. National Library of Medicine. Retrieved 9 December 2014.
- ↑ Crow, MK; Olferiev, M; Kirou, KA (16 October 2014). "Targeting of type I interferon in systemic autoimmune diseases.". Translational Research. PMID 25468480. doi:10.1016/j.trsl.2014.10.005.